701232-67-9

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-((1s,4s)-4-(4-hydroxyphenyl)cyclohexyl)acetate is used as a potential pharmaceutical compound for its possible biological activity, which may contribute to the development of new drugs or therapeutic agents. The presence of cyclohexyl and hydroxyphenyl groups could offer unique interactions with biological targets, making it a candidate for further exploration in drug discovery.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Methyl 2-((1s,4s)-4-(4-hydroxyphenyl)cyclohexyl)acetate is used as a research tool to understand the role of cyclohexyl and hydroxyphenyl groups in biological processes. This understanding can aid in the design of more effective and targeted pharmaceuticals.
Used in Drug Development:
Methyl 2-((1s,4s)-4-(4-hydroxyphenyl)cyclohexyl)acetate is utilized in drug development as a lead compound. Its complex structure and potential biological activity make it a valuable starting point for the synthesis of new drugs with improved efficacy and selectivity.
Note: Since the provided materials do not specify particular applications or industries for Methyl 2-((1s,4s)-4-(4-hydroxyphenyl)cyclohexyl)acetate, the uses listed are inferred based on the compound's potential properties and common practices in the pharmaceutical and medicinal chemistry fields. Further information would be required to detail specific applications.

Upstream product

• 1245708-05-7 methyl 2-(4-(4-hydroxyphenyl)cyclohexyl)acetate 
• 701232-66-8 [4-(4-hydroxyphenyl)cyclohexylidene]acetic acid methyl ester 
• 105640-07-1 4-(4-hydroxyphenyl)cyclohexan-1-one 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 

Downstream Products

• 701232-68-0 (trans)-methyl 2-(4-(4-(((trifluoromethyl)sulfonyl)oxy)phenyl)cyclohexyl)acetate 
• 1109277-50-0 methyl (trans-4-{4-[(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]phenyl}cyclohexyl)acetate 
• 1394002-56-2 methyl (trans-4-{4-[(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl){[4,6-dichloro-2-(methylsulfanyl)-pyrimidin-5-yl]carbonyl}amino]phenyl}cyclohexyl)acetate 
• 1394002-57-3 methyl (trans-4-{4-[{[4,6-dichloro-2-(methylsulfanyl)pyrimidin-5-yl]carbonyl}(2-hydroxyethyl)amino]phenyl}cyclohexyl)acetate 
• 1394002-58-4 methyl (trans-4-{4-[4-chloro-2-(methylsulfanyl)-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl]phenyl}cyclohexyl)acetate 
• 1394002-59-5 methyl (trans-4-{4-[4-amino-2-(methylsulfanyl)-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl]phenyl}cyclohexyl)acetate 
• 1394002-60-8 (trans-4-{4-[4-amino-2-(methylsulfanyl)-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl]phenyl}cyclohexyl)acetic acid 
• 1394002-61-9 (trans-4-{4-[4-amino-2-(methylsulfonyl)-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl]phenyl}cyclohexyl)acetic acid 
• 1398551-70-6 (trans-4-{4-[4-amino-2-(3-methylbutoxy)-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl]phenyl}cyclohexyl)acetic acid trifluoroacetate 
• 1245708-73-9 2-((1r,4r)-4-(4-(1-(phenylcarbamoyl)-1H-indol-5-yl)phenyl)cyclohexyl)acetic acid 
• 1245708-75-1 2-((1r,4r)-4-(4-(4-(phenylcarbamoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl) phenyl) cyclohexyl)acetic acid 
• 1245708-08-0 4-((1r,4r)-4-(2-methoxy-2-oxoethyl)cyclohexyl)phenylboronic acid 
• 1245708-77-3 2-((1r,4r)-4-(4-(4-(phenylcarbamoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)phenyl) cyclohexyl)acetic acid 
• 1245708-78-4 2-((1r,4r)-4-(4-(4-(phenylcarbamoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)phenyl)cyclohexyl)acetic acid 

Relevant academic research and scientific papers

NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts the

Development of novel benzomorpholine class of diacylglycerol acyltransferase i inhibitors

Diacylglycerol acyltransferase 1 (DGAT1) presents itself as a potential therapeutic target for obesity and diabetes for its important role in triglyceride biosynthesis. Herein we report the rational design of a novel class of DGAT1 inhibitors featuring a

Discovery of 6-phenylpyrimido[4,5- B ][1,4]oxazines as potent and selective Acyl CoA: Diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents

The discovery and optimization of a series of acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors based on a pyrimido[4,5-b][1,4]oxazine scaffold is described. The SAR of a moderately potent HTS hit was investigated resulting in the discovery of phenylcyclohexylacetic acid 1, which displayed good DGAT1 inhibitory activity, selectivity, and PK properties. During preclinical toxicity studies a metabolite of 1 was observed that was responsible for elevating the levels of liver enzymes ALT and AST. Subsequently, analogues were synthesized to preclude the formation of the toxic metabolite. This effort resulted in the discovery of spiroindane 42, which displayed significantly improved DGAT1 inhibition compared to 1. Spiroindane 42 was well tolerated in rodents in vivo, demonstrated efficacy in an oral triglyceride uptake study in mice, and had an acceptable safety profile in preclinical toxicity studies.

Proton exchange reactions in isotope chemistry (II) synthesis of stable isotope-labeled LCQ908

The proton exchange reaction was applied to the preparation of stable isotope-labeled LCQ908. For this synthesis, a suitable intermediate with protons alpha to a carbonyl group was first subjected to the H-D exchange reaction; subsequent coupling of a car

4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5, 4 -F] [1, 4] OXAZEPINE COMPOUNDS AS DGAT1 INHIBITORS

Described herein are compounds of formula (I). The compounds of formula (I) act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

LACTAM DERIVATIVES AS DGAT-1 INHIBITORS

Described herein are compounds of formula I The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

COMPOSITIONS AND METHODS FOR MODULATING LPA RECEPTORS

The present invention relates to compounds of Formula (1), or pharmaceutically acceptable salts thereof and their pharmaceutical compositions, wherein variables are as defined herein, which are useful as modulators of the activity of lysophosphatidic acid (LPA).

CRYSTALLINE FORM OF (TRANS-4- [ ( { 5- [ (3, 4 -DI FLUOROPHENYL) AMINO] -1,3, 4-OXADIAZOL-2-YL}CARBONYL) AMINO] PH ENYL } CYCLOHEXYL) ACETIC ACID

Novel crystalline forms of the compound (trans-4- {4-[({5-[(3,4-difluorophenyl)amino]- 1,3,4-oxadiazol-2-yl}carbonyl)amino]phenyl}cyclohexyl)acetic acid are provided, together with processes for the manufacture of such forms, pharmaceutical compositions c

BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES

Compounds of formula (I), or salts thereof, which inhibit acetyl CoA(acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, (A chemical formula should be inserted here - please see paper copy enclosed herewith) (I) wherein: Rsup